TY - JOUR
T1 - Prognostic value of TTF-1 expression in patients with non-small cell lung cancer
T2 - A meta-analysis
AU - Zhan, Ping
AU - Qian, Qian
AU - Wan, Benjamin
AU - Yan, Tristan D.
AU - Yu, Li Ke
PY - 2013/2/1
Y1 - 2013/2/1
N2 - Background: Observational studies on the prognostic role of thyroid transcription factor 1 (TTF-1) in non-small cell lung cancer (NSCLC) are controversial. Methods: To clarify the impact of TTF-1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios and their corresponding 95% confidence intervals were calculated in terms of overall survival. Results: A total of 17 studies with 2,235 patients were evaluable for this meta-analysis. The studies were categorized by histology, disease stage and patient race. Our results suggested that TTF-1 overexpression had a favorable impact on survival of patients with NSCLC, the HR (95% CI) was 0.49 (0.42 to 0.55) overall, 0.46 (0.38-0.54) in Asian patients, 0.52 (0.42-0.63) in non-Asian patients, 0.45 (0.38-0.52) in adenocarcinoma, 0.63 (0.39-0.86) in stage I NSCLC, 0.43 (0.33-0.53) in stage IIIb-IV NSCLC. The data collected were not sufficient to determine the prognostic value of VEGF in patients with squamous cell lung carcinomas. But there was a high heterogeneity between the studies. Conclusions: TTF-1 overexpression indicates a favorable prognosis for patients with NSCLC, this effect appears also significant when the analysis is restricted in lung AC patients, stage I and stage IIIb-IV NSCLC.
AB - Background: Observational studies on the prognostic role of thyroid transcription factor 1 (TTF-1) in non-small cell lung cancer (NSCLC) are controversial. Methods: To clarify the impact of TTF-1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios and their corresponding 95% confidence intervals were calculated in terms of overall survival. Results: A total of 17 studies with 2,235 patients were evaluable for this meta-analysis. The studies were categorized by histology, disease stage and patient race. Our results suggested that TTF-1 overexpression had a favorable impact on survival of patients with NSCLC, the HR (95% CI) was 0.49 (0.42 to 0.55) overall, 0.46 (0.38-0.54) in Asian patients, 0.52 (0.42-0.63) in non-Asian patients, 0.45 (0.38-0.52) in adenocarcinoma, 0.63 (0.39-0.86) in stage I NSCLC, 0.43 (0.33-0.53) in stage IIIb-IV NSCLC. The data collected were not sufficient to determine the prognostic value of VEGF in patients with squamous cell lung carcinomas. But there was a high heterogeneity between the studies. Conclusions: TTF-1 overexpression indicates a favorable prognosis for patients with NSCLC, this effect appears also significant when the analysis is restricted in lung AC patients, stage I and stage IIIb-IV NSCLC.
KW - Lung cancer
KW - Meta-analysis
KW - Prognosis
KW - Thyroid transcription factor 1
UR - http://www.scopus.com/inward/record.url?scp=84962759517&partnerID=8YFLogxK
U2 - 10.3978/j.issn.2218-676X.2013.02.08
DO - 10.3978/j.issn.2218-676X.2013.02.08
M3 - Article
AN - SCOPUS:84962759517
SN - 2218-676X
VL - 2
SP - 25
EP - 32
JO - Translational Cancer Research
JF - Translational Cancer Research
IS - 1
ER -